Projects & Grants

Internal Grant Competition DGC
START-UP grant

Malign potential of non-alcoholic fatty liver disease in patients with obesity and Metabolic syndrome - diagnostic management
Project IdSGS03/LF/2018
Main solverMUDr. Daniel Toman, Ph.D.
Period1/2018 - 12/2018
ProviderSpecifický VŠ výzkum
AnotationThe aim of the research is to diagnose the condition and function of the liver parenchyma in the selected population, which is most likely to be endangered by the development of progressive liver failure with all consequences until the development of hepatocellular carcinoma (HCC). The target population would be patients with obesity and metabolic syndrome (MS). The global prevalence of obesity has almost tripled between 1975 and 2016. In the Czech Republic, about 25% of women and 22% of men are affected by obesity. With the increasing incidence of obesity, there is an increase of liver steatosis. This has become the most common chronic liver disease in developed countries, even in patients who do not drink alcohol at all. In most cases, non-alcoholic fatty liver disease (NAFLD) is a benign and reversible liver disorder.Under certain circumstances, an inflammatory component may be added to the steatosis, and the disease may result, through the image of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis, to liver cirhosis with all known negative consequences, until the developement of HCC. HCC patients with clinical symptoms have a very poor prognosis (the median 5-year overall survival (OS) is 0-10%); on the other hand, patients with asymptomatic HCC detected by screening show a higher survival rate (5- year OS is more than 50 %) due to radical treatment. Although the liver biopsy remains the gold standard for NAFLD diagnosis, it seems that new diagnostic methods, that could distinguish simple steatosis from NASH, are emerging. Drug therapy have been utilized to ameliorate MS, also lipid-lowering drugs are used, and many other promising drugs are still tested.Ther is an importance of lifestyle changes that leads to weight reduction. The final non-invasive diagnosis scheme could be used across a wide range of patients and thus systematically prevent the development of diseases and related disorders that are, in their progression, more expensive for treatment.